Frontline Maintenance Treatment for Ovarian Cancer
Open Access
- 14 June 2021
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 23 (8) , 1-10
Abstract
Purpose of Review: Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival. Recent Findings: Here we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy. Summary: Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.Keywords
This publication has 70 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysisGynecologic Oncology, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group TrialJournal of Clinical Oncology, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003